论文部分内容阅读
资料来源:FDA网站发布时间:2012.1.27美国食品药品监督管理局于今天批准Inlyta(阿西替尼)用于治疗其他药物治疗无效的晚期肾癌(肾细胞癌)。阿西替尼通过阻断肿瘤生长过程中的蛋白激酶起到抑制肿块生长和癌症进展的作用。阿西替尼为一日两片的片剂。“这是自2005来FDA批准用于治疗转移或晚期肾细胞癌的第7种药物。”FDA药物评价和研究中心心血管和肿瘤学办公室主任,医学博士Richard Pazdur说。“总的来说,在这段时间内的药物开
Source: FDA Published: 2012.1.27 The U.S. Food and Drug Administration (FDA) today approved Inlyta for the treatment of advanced renal cell carcinoma (renal cell carcinoma) that is refractory to other medical treatments. Axitinib acts to inhibit tumor growth and cancer progression by blocking protein kinases in tumor growth. Axitinib tablets for two tablets a day. ”This is the seventh FDA-approved drug to treat metastatic or advanced renal cell carcinoma since 2005,“ said Richard Pazdur, MD, director of the Office of Cardiovascular and Oncology at the FDA Center for Drug Evaluation and Research. ”In general, during this time the drug is on